Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Recentness of the research fronts detected by usage count_
| Clusters | No. of references | Mean cited year | No. of citing articles | Recentness |
|---|---|---|---|---|
| Clinic | 5 | 2012 | 39 | 2014.35 |
| Whole organ engineering | 25 | 2011 | 39 | 2013.77 |
| Expansion | 22 | 2011 | 55 | 2013.46 |
| Hydrogel | 27 | 2010 | 52 | 2013.32 |
| Overview | 26 | 2010 | 36 | 2013.21 |
| Extracellular vesicle | 26 | 2010 | 49 | 2013.02 |
| Regulating stem cell fate | 23 | 2010 | 61 | 2013.00 |
| Induction | 23 | 2010 | 44 | 2013.00 |
| Induced pluripotent stem cell differentiation | 21 | 2010 | 38 | 2013.00 |
| Carbon nanotube | 19 | 2010 | 40 | 2012.72 |
| Human pluripotent stem | 19 | 2010 | 22 | 2012.60 |
| Stem cell application | 26 | 2009 | 39 | 2012.28 |
| Peptide | 24 | 2009 | 32 | 2012.05 |
| Porous scaffold | 21 | 2009 | 42 | 2011.81 |
| Poly | 5 | 2009 | 35 | 2011.50 |
| Layer | 27 | 2008 | 66 | 2011.49 |
| Biomedicine | 25 | 2008 | 57 | 2011.31 |
| Induced pluripotent stem cell | 25 | 2008 | 36 | 2011.13 |
| Glycosaminoglycan-binding substratum | 24 | 2008 | 36 | 2011.09 |
| Pro-angiogenic properties | 26 | 2007 | 27 | 2010.96 |
| Nanotechnologies | 16 | 2007 | 34 | 2010.23 |
| Water filtration | 31 | 2005 | 51 | 2010.20 |
| Supramolecular design | 25 | 2005 | 20 | 2010.02 |
| Biodegradable hydrogel | 24 | 2005 | 8 | 2009.90 |
| Present status | 21 | 2004 | 20 | 2009.37 |
| Biological characterization | 5 | 1998 | 3 | 2002.67 |
| Mean value of all clusters | 21.58 | 2008.19 | 37.73 | 2011.59 |
Top 10 highly cited papers detected by usage count and times cited_
| Articles detected by times cited | Articles detected by usage count | ||||
|---|---|---|---|---|---|
| Frequency | Articles | Publishing year | Frequency | Articles | Publishing year |
| 225 | Takahashi, K., Cell, V126, P663 | 2006 | 168 | Takahashi, K., Cell, V131, P861 | 2007 |
| 212 | Takahashi, K., Cell, V131, P861 | 2007 | 155 | Engler, A.J., Cell, V126, P677 | 2006 |
| 188 | Yu, J.Y., Science, V318, P1917 | 2007 | 110 | Slaughter, B.V., Bvadv Mater, V21, P3307 | 2009 |
| 115 | Engler, A. J., Cell, V126, P677 | 2006 | 107 | Yu, J.Y., Science, V318, P1917 | 2007 |
| 113 | Dominici, M., Mcytotherapy, V8, P315 | 2006 | 104 | Takahashi, K., Cell, V126, P663 | 2006 |
| 106 | Jiang, Y.H., Nature, V418, P41 | 2002 | 77 | Dalby, M.J., Nat Mater, V6, P997 | 2007 |
| 99 | Okita, K., Nature, V448, P313 | 2007 | 74 | Ott, H.C., Nat Med, V14, P213 | 2008 |
| 91 | Park, I.H., Nature, V451, P141 | 2008 | 63 | Lutolf, M.P., Nat Biotechnol, V23, P47 | 2005 |
| 89 | Pittenger, M.F., Science, V284, P143 | 1999 | 61 | Discher, D.E., Science, V324, P1673 | 2009 |
| 86 | Thomson, J.A., Science, V282, P1145 | 1998 | 55 | Macchiarini, P., Lancet, V372, P2023 | 2008 |
| Mean year | 2004.6 | Mean year | 2007.2 | ||
Overview of the dataset_
| Times cited | Usage count | |
|---|---|---|
| No. of cited references | 84,315 | 113,339 |
| Recentness | 2009.0 | 2013.3 |
| Mean publication year of cited references | 2002.6 | 2005.7 |
Recentness of the research fronts detected by times cited_
| Clusters | No. of references | Mean cited year | No. of citing articles | Recentness |
|---|---|---|---|---|
| Emerging peptide nanomedicine | 29 | 2008 | 54 | 2010.44 |
| Pluripotent stem cell | 25 | 2007 | 56 | 2008.89 |
| Adipose-derived stem cell | 25 | 2003 | 83 | 2010.14 |
| Somatic cell | 22 | 2008 | 52 | 2009.33 |
| Mesenchymal stem cell | 22 | 2003 | 55 | 2010.07 |
| Induced pluripotent stem cell | 22 | 2008 | 41 | 2009.05 |
| Embryonic stem cell | 22 | 2004 | 60 | 2010.08 |
| Organ level tissue engineering | 21 | 2008 | 50 | 2009.80 |
| Mesenchymal stromal cell | 21 | 2005 | 52 | 2009.33 |
| Synthetic hydrogels | 21 | 2002 | 48 | 2010.45 |
| Hippo pathway | 20 | 2008 | 52 | 2010.69 |
| Human induced pluripotent stem cell | 19 | 2009 | 64 | 2010.36 |
| Human embryonic stem cells | 18 | 2007 | 40 | 2008.05 |
| Regenerative biology | 18 | 2001 | 51 | 2010.25 |
| Marrow-derived mesenchymal cell | 18 | 2001 | 38 | 2007.34 |
| Human wharton | 17 | 2006 | 27 | 2010.00 |
| Genetic modification | 17 | 2002 | 31 | 2007.81 |
| Generation | 16 | 2008 | 40 | 2007.40 |
| Therapeutic application | 16 | 2002 | 41 | 2010.00 |
| Review | 8 | 2000 | 8 | 2002.00 |
| Mean value of all clusters | 19.85 | 2005 | 47.15 | 2009.07 |
Comparison of the top 10 citing papers of the common research front_
| Times cited | Usage count | ||||
|---|---|---|---|---|---|
| Coverage (%) | Citing articles | Publishing year | Coverage (%) | Citing articles | Publishing year |
| 55 | Wang, Y. A transcriptional roadmap to the induction of pluripotency in somatic cells. | 2010 | 40 | Patel, M. Advances in reprogramming somatic cells to induced pluripotent stem cells. | 2010 |
| 50 | Kiskinis, E. Progress toward the clinical application of patient-specific pluripotent stem cells. | 2010 | 32 | Warren, L. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. | 2010 |
| 50 | Li, W.L. Small molecules that modulate embryonic stem cell fate and somatic cell reprogramming. | 2010 | 24 | Ben-David, U. The tumorigenicity of human embryonic and induced pluripotent stem cells. | 2011 |
| 50 | Masip, M. Reprogramming with defined factors: From induced pluripotency to induced transdifferentiation. | 2010 | 20 | Lister, R. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. | 2011 |
| 45 | Warren, L. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. | 2010 | 20 | Tsuji, O. Therapeutic potential of appropriately evaluated safe-induced pluripotent stem cells for spinal cord injury. | 2010 |
| 41 | Cox, J.L. Induced pluripotent stem cells: What lies beyond the paradigm shift. | 2010 | 20 | Wu, S.M. Harnessing the potential of induced pluripotent stem cells for regenerative medicine. | 2011 |
| 41 | Lengner, C. J. IPS cell technology in regenerative medicine. | 2010 | 16 | Zhao, T.B. Immunogenicity of induced pluripotent stem cells. | 2011 |
| 41 | Tamaoki, N. Dental pulp cells for induced pluripotent stem cell banking. | 2010 | 12 | Young, R. A. Control of the embryonic stem cell state. | 2011 |
| 36 | Chun, Y.S. Applications of patient-specific induced pluripotent stem cells; focused on disease modeling, drug screening and therapeutic potentials for liver disease. | 2010 | 8 | Burridge, P.W. A universal system for highly efficient cardiac differentiation of human induced pluripotent stem cells that eliminates interline variability. | 2011 |
| 36 | Nakagawa, M. Promotion of direct reprogramming by transformation-deficient myc. | 2010 | 8 | Klim, J.R. A defined glycosaminoglycan-binding substratum for human pluripotent stem cells. | 2010 |
| Recentness | 2010.07 | Recentness | 2011.09 | ||